The first Russian intradermal implant has successfully passed the state registration. This product has been developed over the past three years with the support of the Russian Ministry of Industry and Trade.
In the future, once the enterprise reaches its production capacity, it will employ only local specialists from Penza. The program provides for gradual increase of production capacity over a two-year period.
NPO Microgen has begun phase 2 clinical trials of the first Russian polysaccharide meningococcal vaccine to prevent diseases caused by Neisseria meningitidis serogroups A and C, including meningitis and meningococcemia.
On March 23, Noroorlovskaya Special Economic Zone in St. Petersburg will host an official ceremony marking the launch of construction of IMMUNO-GEM, a production facility for human blood plasma-derived medicines.
Kaluga pharmaceutical cluster recently increased the number of locally manufactured drugs from 65 to 154. The Governor expects that the region needs 2 years to complete its import substitution program for radiopharmaceuticals.